Emmes has created the Emmes Group comprised of two business units: Emmes, its clinical research organization (CRO) led by Peter Ronco, and Veridix AI, the newly launched technology and artificial intelligence (AI) group, led by recently appointed executive Rama Kondru. Emmes has also named Sastry Chilukuri Executive Chairman and CEO and Matthew Holt to its board of directors.

“We have an opportunity to advance Emmes’ 47-year legacy of excellence in clinical research by building the clinical research infrastructure of the future,” said Chilukuri. “Our new Veridix AI business unit will embed technology and generative AI into all aspects of clinical trials. Emmes is a full-service CRO with more than 1,600 employees, supporting clinical research in over 70 countries. We are one of the top clinical service providers to the U.S. government with industry-leading capabilities in cell and gene therapy, vaccines and infectious diseases, and ophthalmology.”